Quarterly ResultMay 7, 2026, 07:08 AM
Apyx Medical Q1 Revenue $12.5M, Raises FY26 Guidance
AI Summary
Apyx Medical Corporation reported strong first-quarter 2026 financial results, with total revenue increasing 32.4% to $12.5 million, primarily driven by a 36.1% growth in its Surgical Aesthetics segment. The company significantly reduced its net loss to $2.1 million and its Adjusted EBITDA loss to $0.3 million compared to the prior year. Following this performance, Apyx Medical raised its full-year 2026 total revenue guidance to a range of $59.0 million to $60.0 million.
Key Highlights
- Apyx Medical reported Q1 2026 total revenue of $12.5 million, a 32.4% increase from $9.4 million in Q1 2025.
- Surgical Aesthetics revenue grew 36.1% to $10.7 million in Q1 2026, driven by AYON and international Renuvion sales.
- OEM revenue increased 13.8% to $1.8 million in Q1 2026.
- Net loss attributable to stockholders improved to $2.1 million ($0.05 per share) from $4.2 million ($0.10 per share) in Q1 2025.
- Adjusted EBITDA loss significantly reduced to $0.3 million in Q1 2026 from $2.4 million in Q1 2025.
- The company raised its full-year 2026 total revenue guidance to a range of $59.0 million to $60.0 million.
- Surgical Aesthetics revenue guidance for FY2026 was raised to $54.0 million to $55.0 million.
- Cash and cash equivalents stood at $31.1 million as of March 31, 2026.